South Africa's Gauteng surpasses first-month targets for HIV-prevention drug lenacapavir
South Africa's Gauteng Department of Health says it has comfortably surpassed its targets in the first month of rolling out lenacapavir, a groundbreaking HIV-prevention drug. The long-acting injectable is seen as a powerful tool for preventing new HIV infections. The early success is considered a significant milestone for the country's preventive health efforts.
South Africa's Gauteng Department of Health has announced it reached a significant milestone in its rollout of lenacapavir, a groundbreaking HIV-prevention drug. The department said it comfortably surpassed the targets it had set in the programme's first month.
Lenacapavir is administered as a long-acting injectable and is regarded as an effective way to prevent new HIV infections. Because it requires doses less frequently than a daily pill, it is seen as improving both accessibility and adherence to the programme.
South Africa is among the countries with the world's highest HIV burden. Officials say this early success in distributing the preventive drug is encouraging for goals of reducing new infections and strengthening public health. The programme is expected to expand to other regions in the coming months.
Read next
Housing crisis in Australia's mining town Nhulunbuy squeezes small businesses
In Australia's Northern Territory mining town of Nhulunbuy, a government-funded housing provider is being criticised for "not doing enough" to support small business owners. A shortage of housing in the region is squeezing the businesses the local economy depends on. The Northern Territory government and the housing fund are at odds over the issue.
New Zealand power company Genesis pushes to ban incandescent light bulbs
Nigeria warns mining firms over host-community deals, threatens licence revocation
Panama to build maximum-security prison to isolate jailed crime leaders
